{"id":"NCT00514709","sponsor":"Sanofi Pasteur, a Sanofi Company","briefTitle":"Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB PRP~T Combined Vaccine in Filipino Infants","officialTitle":"Immunogenicity Study of the Antibody Persistence and Booster Effect of DTaP-Hep B-PRP-T Combined Vaccine at 12 to 18 Months of Age Following a Primary Series at 6, 10 and 14 Weeks of Age in Healthy Filipino Infants Having Received Hepatitis B Vaccine at Birth","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-09","primaryCompletion":"2008-12","completion":"2009-04","firstPosted":"2007-08-10","resultsPosted":"2013-11-14","lastUpdate":"2016-08-02"},"enrollment":1843,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Diphtheria","Tetanus","Pertussis","Hepatitis B","Influenza"],"interventions":[{"type":"BIOLOGICAL","name":"DTaP-HB PRP~T Combined Vaccine","otherNames":[]},{"type":"BIOLOGICAL","name":"DTaP-HB-PRP~T vaccine","otherNames":[]},{"type":"BIOLOGICAL","name":"Oral Polio Vaccine","otherNames":[]}],"arms":[{"label":"Group 1","type":"EXPERIMENTAL"},{"label":"Group 2","type":"EXPERIMENTAL"}],"summary":"DTaP-HB-PRP\\~T combined vaccine is being developed in order to comply with expanding programs for immunization in infancy, while offering the benefit of a reduced number of injections, and potentially of an increased acceptance.\n\nPrimary Objectives:\n\n* To describe the antibody persistence at 12 to 18 months following a three-dose primary series vaccination of either DTaP-HB-PRP\\~T or Tritanrix-Hep B/Hib™ given at 6, 10 and 14 weeks of age, and one dose of Hepatitis B (Hep B) vaccine given at birth.\n* To describe the effect of a booster dose of DTaP-HB-PRP\\~T on immunogenicity at 12 to 18 months following a three-dose primary series vaccination of either DTaP-HB-PRP\\~T or Tritanrix HepB/Hib™ given at 6, 10 and 14 weeks of age, and one dose of Hep B vaccine given at birth.\n\nSecondary Objective:\n\n* To describe the safety profile of the booster dose of the DTaP-HB-PRP\\~T vaccine when administered concomitantly with Oral Polio Vaccine (OPV).","primaryOutcome":{"measure":"Number of Participants With Antibody Persistence and Immunogenicity Booster Response to Vaccination With DTaP-Hep B-PRP~T Concomitantly With Oral Polio Vaccine (OPV)","timeFrame":"Day 0 (pre-vaccination) and Day 28 post-booster vaccination","effectByArm":[{"arm":"Group 1: DTaP-Hep B-PRP~T + OPV","deltaMin":81,"sd":null},{"arm":"Group 2: Tritanrix-Hep B/ Hib™ + OPV","deltaMin":80,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Months","sex":"ALL","healthyVolunteers":true,"inclusionCount":4,"exclusionCount":13},"locations":{"siteCount":7,"countries":["Philippines"]},"refs":{"pmids":[],"seeAlso":["http://www.sanofipasteur.com"]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":1230},"commonTop":["Solicited injection site Pain","Solicited injection site Erythema","Irritability","Solicited injection site Swelling","Pyrexia"]}}